First Mature Estimation of Median OS for Selpercatinib in Patients with RET Fusion-Positive NSCLC By Ogkologos - March 12, 2025 736 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from final efficacy and safety analyses from the LIBRETTO-001 study Source RELATED ARTICLESMORE FROM AUTHOR Low-Dose Pembrolizumab with Dose-Dense Chemotherapy Increases pCR as Neoadjuvant Treatment for Localised TNBC ESMO Advocates for Equal Access to Optimal Cancer Care for all Patients with Cancer at the 79th World Health Assembly Daraxonrasib Shows Antitumour Activity Among Patients with Previously Treated RAS-mutated Pancreatic Ductal Adenocarcinoma MOST POPULAR The (un)usual suspects – how early detection research embraces interdisciplinary science August 20, 2021 Should alcohol marketing be dropped from televised sport? August 27, 2021 Sugar and cancer – what you need to know October 20, 2020 EMA Recommends Extension of Indications for Crizotinib September 23, 2022 Load more HOT NEWS New on NCI’s Websites for June 2023 Data from a Large Cohort of Patients with mRCC Demonstrate the... Adding Pembrolizumab to Chemotherapy with or without Bevacizumab Improves Overall Survival... Coffee Shop Owner Learns He Has Terminal Cancer – So Competitor...
